Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aevi Genomic Medicine Inc (GNMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011861
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company’s pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network. Aevi’s product candidate AEVI-002, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. It collaborates with other research institutes and companies. Aevi is headquartered in Wayne, Pennsylvania, the US.

Aevi Genomic Medicine Inc (GNMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aevi Genomic Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Medgenics Enters into Agreement with Kyowa Hakko Kirin 12
Medgenics Enters into Agreement with Harvard University 13
Medgenics Extends Co-Development Agreement With Baxter Healthcare 14
Licensing Agreements 15
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 15
Medgenics Enters into Licensing Agreement with Stanford University 16
Aevi Genomic Medicine Amends its Agreement with Children’s Hospital of Philadelphia 17
Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 18
Equity Offering 19
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 19
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 20
Medgenics Raises USD20 Million in Public Offering of Shares 21
Medgenics Raises USD46 Million in Public Offering of Shares 23
Medgenics Raises USD24.2 Million in Public Offering of Shares 25
Medgenics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 27
Medgenics Completes Private Placement Of Units For US$9.5 Million 29
Medgenics Issues Additional Shares Upon Partial Exercise Of Underwriter’s Over Allotment Option 30
Acquisition 32
Medgenics Acquires NeuroFix Therapeutics 32
Aevi Genomic Medicine Inc – Key Competitors 33
Aevi Genomic Medicine Inc – Key Employees 34
Aevi Genomic Medicine Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 02, 2017: Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results 36
Aug 09, 2017: Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results 37
May 10, 2017: Aevi Genomic Medicine Announces First Quarter 2017 Operating Results 38
May 10, 2017: Aevi Genomic Medicine Q1 net loss decreases 39
Mar 09, 2017: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 40
Nov 03, 2016: Medgenics Reports Third Quarter 2016 Financial Results 42
Aug 04, 2016: Medgenics Reports Second Quarter 2016 Financial Results 44
May 10, 2016: Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update 45
Feb 17, 2016: Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs 47
Corporate Communications 50
Dec 04, 2017: Aevi Genomic Medicine Announces New Appointment to its Board of Directors 50
Oct 10, 2016: Medgenics to Begin Trading on NASDAQ Global Market 51
Feb 03, 2016: Medgenics Promotes Brian Piper to Chief Financial Officer 52
Product News 53
10/29/2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 53
Other Significant Developments 54
Dec 15, 2016: Medgenics Announces Name Change to Aevi Genomic Medicine 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aevi Genomic Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aevi Genomic Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Medgenics Enters into Agreement with Kyowa Hakko Kirin 12
Medgenics Enters into Agreement with Harvard University 13
Medgenics Extends Co-Development Agreement With Baxter Healthcare 14
NeuroFix Therapeutics Enters into Licensing Agreement with Lipopharma Therapeutics 15
Medgenics Enters into Licensing Agreement with Stanford University 16
Aevi Genomic Medicine Amends its Agreement with Children's Hospital of Philadelphia 17
Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 18
Aevi Genomic Medicine Plans to Raise Funds in Secondary Offering of Shares 19
Aevi Genomic Medicine to Raise USD28 Million in Private Placement of Shares and Warrrants 20
Medgenics Raises USD20 Million in Public Offering of Shares 21
Medgenics Raises USD46 Million in Public Offering of Shares 23
Medgenics Raises USD24.2 Million in Public Offering of Shares 25
Medgenics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 27
Medgenics Completes Private Placement Of Units For US$9.5 Million 29
Medgenics Issues Additional Shares Upon Partial Exercise Of Underwriter's Over Allotment Option 30
Medgenics Acquires NeuroFix Therapeutics 32
Aevi Genomic Medicine Inc, Key Competitors 33
Aevi Genomic Medicine Inc, Key Employees 34
Aevi Genomic Medicine Inc, Subsidiaries 35

★海外企業調査レポート[Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■

◆H&Iグローバルリサーチ株式会社のお客様(例)◆